News for IGM Biosciences, Inc. (IGMS)

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing conti

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Igm biosciences principal accounting officer sells $1,907 in stock

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street downgrades. Read more here.

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 400 points on Friday. The Dow traded down 1.19% to 42,129.32 while t...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 400 points on Friday. The Dow traded down 1.64% to 41,935.30 while the ...

U.S. stocks traded lower this morning, with the Dow Jones index falling around 500 points on Friday. The Dow traded down 1.18% to 42,130.51 while the NASDAQ di...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.S. stock futures were on a mixed note on Friday ahead of the crucial U.S. jobs data report after a mixed close in the previous session.

Shares of Zoomcar Holdings Inc ZCAR rose sharply in today's pre-market trading after the company announced a significant achievement in its financial performanc...

U.S. stocks were lower, with the Dow Jones index falling around 50 points on Tuesday. Shares of Quest Diagnostics Incorporated DGX rose sharply during Tuesday'...

The allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in...

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Tuesday. Shares of PepsiCo, Inc. PEP rose during Tuesday's session following the...

The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...

Loading... Loading... Shares of Conagra Brands, Inc. CAG fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales res...

Loading... Loading... Shares of XP Inc. XP fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. X...